Pulmonary Hemorrhage in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Single-Center Retrospective Study

Yogi Chopra,Amal Alsabahi,Tal Schechter,Haifa Mtaweh,Neil Sweezey,Corinne Balit,Muhammad Ali,Kuang-Yueh Chiang,Adam Gassas,Joerg Krueger
DOI: https://doi.org/10.1097/PCC.0000000000003350
2024-01-01
Abstract:Objectives: Pulmonary hemorrhage (PH) is a serious complication posthematopoietic stem cell transplant (HSCT). In view of limited available pediatric data, we performed a retrospective study to describe epidemiology, management, and outcomes of PH post-HSCT in children in our national center. Design: Retrospective study. Setting: Academic children's hospital (2000-2015). Subjects: Children (< 18 yr) with PH and requiring PICU care post-HSCT. Interventions: None. Measurements and main results: The historical prevalence of PH in our center was 2.7% (31/1,148). Twenty patients had a concomitant infection, 15 had bacterial infection, 8 had viral infection, and 3 patients had a fungal infection. With a median follow-up time of 60 months, 7 of 31 patients were alive. Early PH (< 40 d post-HSCT) was associated with improved survival (6/15 vs 1/16, p = 0.035). Patients who received high-dose pulsed corticosteroid had improved survival when compared with those who did not (7/22 vs 0/9, p = 0.0012); this also applied to the subgroup of patients with a concomitant infection (5/15 vs 0, p = 0.001). None of the patients who survived had measurable respiratory sequelae. Conclusions: PH is a rare but serious complication after HSCT. Corticosteroids were associated with improved survival even in patients with a concomitant infection.
What problem does this paper attempt to address?